본문 바로가기 주메뉴 바로가기
22대 대한민국 국회 국회정보길라잡이 국회의원검색
회원가입 로그인
HOME

정보검색

소장정보 검색

국회도서관 홈으로 정보검색 소장정보 검색
결과 내 검색 동의어 포함
결과 내 검색 동의어 포함

-

초록보기

Purpose This study aimed to assess the real-world clinical outcomes of consolidative durvalumab in patients with unresectable locally advanced non–small cell lung cancer (LA-NSCLC) and to explore the role of radiotherapy in the era of immunotherapy.

Materials and Methods This retrospective study assessed 171 patients with unresectable LA-NSCLC who underwent concurrent chemoradiotherapy (CCRT) with or without consolidative durvalumab at Asan Medical Center between May 2018 and May 2021. Primary outcomes included freedom from locoregional failure (FFLRF), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS).

Results Durvalumab following CCRT demonstrated a prolonged median PFS of 20.9 months (p=0.048) and a 3-year FFLRF rate of 57.3% (p=0.008), compared to 13.7 months and 38.8%, respectively, with CCRT alone. Furthermore, the incidence of in-field recurrence was significantly greater in the CCRT-alone group compared to the durvalumab group (26.8% vs. 12.4%, p=0.027). While median OS was not reached with durvalumab, it was 35.4 months in patients receiving CCRT alone (p=0.010). Patients positive for programmed cell death ligand 1 (PD-L1) expression showed notably better outcomes, including FFLRF, DMFS, PFS, and OS. Adherence to PACIFIC trial eligibility criteria identified 100 patients (58.5%) as ineligible. The use of durvalumab demonstrated better survival regardless of eligibility criteria.

Conclusion The use of durvalumab consolidation following CCRT significantly enhanced locoregional control and OS in patients with unresectable LA-NSCLC, especially in those with PD-L1–positive tumors, thereby validating the role of durvalumab in standard care.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
HER2-low breast cancer : now and in the future Sora Kang, Sung-Bae Kim p. 700-720

Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer : a joint report from KSMO and KSP Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo ... [et al.] p. 721-742

Phase 1/2a study of rivoceranib, a selective VEGFR-2 angiogenesis inhibitor, in patients with advanced solid tumors Yoon-Koo Kang, Min-Hee Ryu, Yong Sang Hong, Chang-Min Choi, Tae Won Kim, Baek-Yeol Ryoo, Jeong Eun Kim, John R. Weis, Rachel Kingsford, Cheol Hee Park, Seong Jang, Arlo McGinn, Theresa L. Werner, Sunil Sharma p. 743-750

Association of immune-related adverse events and the efficacy of anti-PD-(L)1 monotherapy in non-small cell lung cancer : adjusting for immortal-time bias Ying Yu, Ning Chen, Sizhe Yu, Wanji Shen, Wanchen Zhai, Hui Li, Yun Fan p. 751-764

Analytical and clinical validation of a highly sensitive NGS-based ctDNA assay with real-world concordance in non-small cell lung cancer Hanbaek Yi, Jeonghwan Youk, Yoojoo Lim, Hanseong Roh, Dongsoo Kyung, Hwang-Phill Kim, Duhee Bang, Bhumsuk Keam, Tae-Min Kim, Miso Kim, Dong-Wan Kim, Tae-You Kim p. 765-773

Comparison of clinicopathogenomic features and treatment outcomes of EGFR and HER2 Exon 20 insertion mutations in non-small cell lung cancer : single-institution experience So Heun Lee, Hyehyun Jeong, Deok Hoon Kim, Se Jin Jang, Sang-We Kim, Shinkyo Yoon, Dae Ho Lee p. 774-784

Contribution of enhanced locoregional control to improved overall survival with consolidative durvalumab after concurrent chemoradiotherapy in locally advanced non-small cell lung cancer : insights from real-world data Jeong Yun Jang, Si Yeol Song, Young Seob Shin, Ha Un Kim, Eun Kyung Choi, Sang-We Kim, Jae Cheol Lee, Dae Ho Lee, Chang-Min Choi, Shinkyo Yoon, Su Ssan Kim p. 785-794

Trastuzumab Biosimilar (HLX02), pertuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer after progression of trastuzumab : a prospective, phase Ⅱ study Ruyan Zhang, Xiaoran Liu, Guohong Song, Yan Zhang, Huiping Li p. 795-801

Implementation of BRCA test among young breast cancer patients in South Korea : a nationwide cohort study Yung-Huyn Hwang, Tae-Kyung Yoo, Sae Byul Lee, Jisun Kim, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Il Yong Chung p. 802-808

(The) clinical efficacy of colorectal cancer patients with pulmonary oligometastases by sterotactic body ablative radiotherapy : a meta-analysis Jae-Uk Jeong, Chai Hong Rim, Gyu Sang Yoo, Won Kyung Cho, Eui Kyu Chie, Yong Chan Ahn, Jong Hoon Lee p. 809-824

(The) persistence of hypertriglyceridemia and the risk of early onset colorectal cancer according to tumor subsites : a nationwide population-based study Young Hoon Chang, Cheol Min Shin, Kyungdo Han, Jin Hyung Jung, Eun Hyo Jin, Joo Hyun Lim, Seung Joo Kang, Yoon Jin Choi, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee p. 825-837

Combined high-dose radiotherapy with sequential gemcitabine-cisplatin based chemotherapy increase the resectability and survival in locally advanced unresectable intrahepatic cholangiocarcinoma : a multi-institutional cohort study Jung Ho Im, Jeong Il Yu, Tae Hyun Kim, Tae Gyu Kim, Jun Won Kim, Jinsil Seong p. 838-846

Global expanded access program for pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma and fibroblast growth factor receptor gene alterations Anouk Lindley, Gerald Prager, Michael Bitzer, Timothy C. Burn, Christine F. Lihou, Elisabeth Croft p. 847-855

Invasiveness of upper tract urothelial carcinoma : clinical significance and integrative diagnostic strategy Bokyung Ahn, Doeun Kim, Kye Jin Park, Ja-Min Park, Sun Young Yoon, Bumsik Hong, Yong Mee Cho, Deokhoon Kim p. 856-870

Adjuvant chemotherapy for upper tract urothelial carcinoma : a real-world, retrospective study Junho Lee, Sung Hee Lim, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park p. 871-876

Single early intravesical instillation of epirubicin for preventing bladder recurrence after nephroureterectomy in upper urinary tract urothelial carcinoma Jong Hoon Lee, Chung Un Lee, Jae Hoon Chung, Wan Song, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Hwan Sung p. 877-884

Bilateral seminal vesicle invasion as a strong prognostic indicator in T3b prostate cancer patients following radical prostatectomy : a comprehensive, multicenter, long-term follow-up study Jungyo Suh, In Gab Jeong, Hwang Gyun Jeon, Chang Wook Jeong, Sangchul Lee, Seong Soo Jeon, Seok-Soo Byun, Cheol Kwak, Hanjong Ahn p. 885-892

Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder : post hoc analysis of two prospective studies Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park p. 893-897

Predicted cervical cancer prevention : impact of national HPV vaccination program on young women in South Korea Kyeongmin Kwak, Seung-sik Hwang p. 898-908

(The) role of early and delayed surgery for infants with congenital brain tumors Jong Seok Lee, Ji Yeoun Lee, Kyung Hyun Kim, Sung-Hye Park, Eun Jung Koh, Seung-Ki Kim, Ji Hoon Phi p. 909-919

Feasibility of circulating tumor DNA analysis in patients with follicular lymphoma Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim p. 920-935

Secondary malignancies in multiple myeloma in Korean patients : a nationwide population-based study Boyoung Park, Eunyoung Lee, Junghyun Yoon, YoungJu Park, Hyeon-Seok Eom p. 936-944

CD19-specific CAR-T cell treatment of 115 children and young adults with acute B lymphoblastic leukemia : long-term follow-up Yu Wang, Yu-juan Xue, Ying-xi Zuo, Yue-ping Jia, Ai-dong Lu, Hui-min Zeng, Le-ping Zhang p. 945-955

Nation-wide retrospective analysis of allogeneic stem cell transplantation in patients with multiple myeloma : a study from Korean Multiple Myeloma Working Party (KMM1913) Ho-Jin Shin, Do-Young Kim, Kihyun Kim, Chang-Ki Min, Je-Jung Lee, Yeung-Chul Mun, Won-Sik Lee, Sung-Nam Lim, Jin Seok Kim, Joon Ho Moon, Da Jung Kim, Soo-Mee Bang, Jong-Ho Won, Jae-Cheol Jo, Young Il Koh p. 956-966

Molecular and treatment characteristics of SMARCB1 or SMARCA4-deficient undifferentiated tumor : retrospective case series Hyeon Gyu Kang, Jiwon Koh, Tae Min Kim, Doo Hee Han, Tae-Bin Won, Dong-Wan Kim, Dong-Young Kim, Bhumsuk Keam p. 967-971

(Correspondence) Bridging the gap between trial adverse events and real-world data Sang Hyuk Kim, Hyun Lee, Dong Won Park p. 972-973

참고문헌 (29건) : 자료제공( 네이버학술정보 )

참고문헌 목록에 대한 테이블로 번호, 참고문헌, 국회도서관 소장유무로 구성되어 있습니다.
번호 참고문헌 국회도서관 소장유무
1 Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25:45-52. 미소장
2 Jung KW, Kang MJ, Park EH, Yun EH, Kim HJ, Kong HJ, et al. Prediction of cancer incidence and mortality in Korea, 2023. Cancer Res Treat. 2023;55:400-7. 미소장
3 Casal-Mourino A, Ruano-Ravina A, Lorenzo-Gonzalez M, Rodriguez-Martinez A, Giraldo-Osorio A, Varela-Lema L, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10:506-18. 미소장
4 Kim HC, Ji W, Lee JC, Kim HR, Song SY, Choi CM, et al. Prognostic factor and clinical outcome in stage III non-small cell lung cancer: a study based on real-world clinical data in the Korean population. Cancer Res Treat. 2021;53:1033-41. 미소장
5 Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919-29. 미소장
6 Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301-11. 미소장
7 Sheldrick RC. Randomized trials vs real-world evidence: how can both inform decision-making? JAMA. 2023;329:1352-3. 미소장
8 Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN Guidelines(R) insights: non-small cell lung cancer, version 2.2023. J Natl Compr Canc Netw. 2023; 21:340-50. 미소장
9 Jang JY, Kim SS, Song SY, Kim YJ, Kim SW, Choi EK. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study. Radiat Oncol. 2021;16:231. 미소장
10 Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123:2756-63. 미소장
11 Mansfield AS, Park SS, Dong H. Synergy of cancer immunotherapy and radiotherapy. Aging (Albany NY). 2015;7:144-5. 미소장
12 Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3:610-9. 미소장
13 Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy. Trends Cancer. 2016;2:286-94. 미소장
14 Mielgo-Rubio X, Rojo F, Mezquita-Perez L, Casas F, Wals A, Juan M, et al. Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck. World J Clin Oncol. 2020;11:898-917. 미소장
15 Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, et al. Rationale and design for a multicenter, phase II study of durvalumab plus concurrent radiation therapy in locally advanced non-small cell lung cancer: The DOLPHIN Study (WJOG11619L). Cancer Manag Res. 2021;13:9167-73. 미소장
16 Zhao B, Li H, Wu J, Ma W. Durvalumab after sequential chemoradiotherapy is safe for stage III, unresectable NSCLC: results from phase 2 PACIFIC-6 trial. J Thorac Oncol. 2023;18:e1-2. 미소장
17 Taugner J, Kasmann L, Eze C, Tufman A, Reinmuth N, Duell T, et al. Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC leads to significant improvement of local-regional control and overall survival in the real-world setting. Cancers (Basel). 2021;13:1613. 미소장
18 Abe T, Saito S, Iino M, Aoshika T, Ryuno Y, Ohta T, et al. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone. Thorac Cancer. 2021;12:245-50. 미소장
19 Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC: an update from the PACIFIC trial. J Thorac Oncol. 2021;16:860-7. 미소장
20 Park CK, Oh HJ, Kim YC, Kim YH, Ahn SJ, Jeong WG, et al. Korean real-world data on patients with unresectable stage III NSCLC treated with durvalumab after chemoradiotherapy: PACIFIC-KR. J Thorac Oncol. 2023;18:1042-54. 미소장
21 Jung HA, Noh JM, Sun JM, Lee SH, Ahn JS, Ahn MJ, et al. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. Lung Cancer. 2020;146:23-9. 미소장
22 Miura Y, Mouri A, Kaira K, Yamaguchi O, Shiono A, Hashimoto K, et al. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: management of adverse events. Thorac Cancer. 2020; 11:1280-7. 미소장
23 Desilets A, Blanc-Durand F, Lau S, Hakozaki T, Kitadai R, Malo J, et al. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: a real-world multicentre study. Eur J Cancer. 2021;142:83-91. 미소장
24 Taugner J, Kasmann L, Eze C, Ruhle A, Tufman A, Reinmuth N, et al. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Invest New Drugs. 2021;39:1189-96. 미소장
25 Tsukita Y, Yamamoto T, Mayahara H, Hata A, Takeda Y, Nakayama H, et al. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: a multi-center retrospective study. Radiother Oncol. 2021;160:266-72. 미소장
26 Guberina M, Guberina N, Pottgen C, Gauler T, Richlitzki C, Metzenmacher M, et al. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. Immunotherapy. 2022; 14:927-44. 미소장
27 Yamamoto T, Tsukita Y, Katagiri Y, Matsushita H, Umezawa R, Ishikawa Y, et al. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice. BMC Cancer. 2022;22:364. 미소장
28 Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, et al. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol. 2023;18:181-93. 미소장
29 Mayahara H, Uehara K, Harada A, Kitatani K, Yabuuchi T, Miyazaki S, et al. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Radiat Oncol. 2022;17:7. 미소장

추천서가 (다양한 추천 자료를 만나보세요)

권호기사보기

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 기사목차